Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences Corp. (EW)
:EW
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.6Last Year’s EPS
0.66Same Quarter Last Year
Moderate Buy
Based on 23 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: 5.36%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive sentiment with strong sales growth, especially in TMTT, strategic acquisitions, and a positive outlook for future growth. Despite some challenges in TAVR growth and regional pressures, the company maintained a strong balance sheet and is optimistic about 2025.Company Guidance
In the call, Edwards Lifesciences provided guidance indicating strong growth and strategic advancements for 2025. The company reported a 9% increase in total sales for both Q4 and the full year 2024, with sales reaching $5.4 billion. For 2025, Edwards projects total company sales to grow between 8% and 10%, targeting $5.6 billion to $6 billion, driven by transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT), with the latter expected to achieve over $500 million in sales. The company also aims for a 27% to 28% adjusted operating margin for the year, leveraging strategic acquisitions and investments in innovative technologies. Edwards anticipates the early TAVR trial results to be a catalyst post-FDA approval in mid-2025, enhancing long-term growth prospects.Strong Full Year Financial Performance
Sales grew 9% to $5.4 billion for 2024, in line with original guidance.
TMTT Outperformance
TMTT sales increased 77% year-over-year to $352 million, exceeding expectations.
Strategic Acquisitions
Completed acquisitions of JC Medical, JenaValve, and Endotronix, expanding opportunities in new therapeutic areas.
Strong Q4 Sales Performance
Total company sales grew 9% in Q4, with higher-than-expected earnings per share.
TAVR Growth and Expansion
TAVR global sales increased 6% year-over-year to $4.1 billion, with strong performance in the U.S. and Europe.
Positive Outlook for 2025
Guidance for 8% to 10% total company sales growth in 2025, with TMTT expected to deliver over $500 million in sales.
Healthy Balance Sheet
Maintained a strong balance sheet with approximately $3 billion in cash and cash equivalents.
---
EW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $70.91 | $75.82 | +6.92% |
| Oct 24, 2024 | $70.35 | $69.38 | -1.38% |
| Jul 24, 2024 | $86.95 | $59.70 | -31.34% |
| Apr 25, 2024 | $88.01 | $86.43 | -1.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Edwards Lifesciences Corp. (EW) report earnings?
Edwards Lifesciences Corp. (EW) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Edwards Lifesciences Corp. (EW) earnings time?
Edwards Lifesciences Corp. (EW) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EW EPS forecast?
EW EPS forecast for the fiscal quarter 2025 (Q1) is 0.6.
---